WO2004042058A2 - Neuartige pufferformulierungen zur isolierung, reinigung und rückgewinnung lang- und kurzkettiger nukleinsäuren - Google Patents
Neuartige pufferformulierungen zur isolierung, reinigung und rückgewinnung lang- und kurzkettiger nukleinsäuren Download PDFInfo
- Publication number
- WO2004042058A2 WO2004042058A2 PCT/DE2003/003728 DE0303728W WO2004042058A2 WO 2004042058 A2 WO2004042058 A2 WO 2004042058A2 DE 0303728 W DE0303728 W DE 0303728W WO 2004042058 A2 WO2004042058 A2 WO 2004042058A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- monovalent
- alcohol
- chloride
- multivalent
- solid phase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
Definitions
- the invention relates to novel formulations of buffers for the isolation, purification and recovery of long- and short-chain nucleic acids.
- the areas of application of the method are all laboratories dealing with nucleic acid isolation, such as forensic medicine, food diagnostics, medical diagnostics, molecular biology, biochemistry, genetic engineering and all other adjacent areas.
- DNA is isolated from cells and tissues by digesting the starting nucleic acid fractions under strongly denaturing and reducing conditions, sometimes also using protein-degrading enzymes
- Phenol / chloroform extraction steps are purified and the nucleic acids are obtained from the aqueous phase by dialysis or ethanol precipitation (Sambrook, J., Fritsch, E.F. and Maniatis, T., 1989, CSH, "Molecular Cloning").
- kits are based on the well-known principle of binding nucleic acids to mineral carriers in the presence of solutions of different chaotropic salts and use as suspension materials suspensions of finely ground glass powder (e.g. Glasmilk, BIO 101, La Jolla, CA), diatomaceous earth (Fa. Sigma ) or silica gel. (Diagen, DE 41 39 664 AI).
- a method for isolating nucleic acids which is practicable for a large number of different applications is shown in US Pat. No. 5,234,809 (Boom).
- a method for isolating nucleic acids from nucleic acid-containing starting materials by incubating the starting material with a chaotropic buffer and a DNA-binding solid phase is described there.
- the chaotropic buffers implement both the lysis of the starting material and the binding of the nucleic acids to the solid phase.
- the method is well suited for isolating nucleic acids from small sample amounts and is particularly useful in the area of isolating viral nucleic acids.
- the physico-chemical principle of the commercially available systems for the isolation of nucleic acids based on the binding of nucleic acids to the surfaces of mineral supports which are used according to the known state of the art, is said to consist in the disruption of superordinate structures of the aqueous environment by which the nucleic acids on the surface of mineral materials, especially glass or. Adsorb silica particles.
- the disturbance of the superordinate structures of the aqueous environment always occurs in the presence of chaotropic ions and is almost quantitative at high concentrations.
- all commercially available systems for isolating nucleic acids contain buffer compositions with high ionic strengths of chaotropic salts, for the binding of nucleic acids to a nucleic acid binding solid phase.
- chaotropic salt solutions eg guanidine isothiocyanate, guandine hydrochloride, sodium perchlorate or sodium iodide
- Chaotropic salts are highly toxic substances.
- the method (like the chaotropic methods) is based on the lysis of the starting material, the binding of the nucleic acid to a mineral carrier material, the subsequent washing of the bound nucleic acids with washing buffers containing ethanol, the removal of ethanol and the final elution of the nucleic acids with an elution buffer of low ionic strength or Water.
- the lysis step is not required for special protocols, for example the isolation of PCR fragments from amplification batches.
- a necessary binding buffer is added to the PCR reaction mixture and incubated with the mineral carrier material. This is followed by washing again with an ethanol-containing washing buffer, followed by ethanol removal and finally the elution of the bound nucleic acid from the carrier material.
- the step of removing residual alcohol is particularly problematic in applications for
- the essence of the invention lies in the simultaneous use of mono- and multi-, preferably divalent, cations for the binding of the nucleic acids to the solid phase.
- Na + , K + and NH 4 + in the form of the corresponding salts are preferably used as monovalent cations.
- Mg 2+ , Ca 2+ , Zn 2+ and Mn 2+ in the form of the corresponding salts are preferably used as divalent cations.
- a particularly preferred embodiment is the combined use of Na + and Mg 2+ .
- the mono- and multi-, preferably divalent, cations can be used in a wide variety of proportions.
- the success occurs in the wide range of mono: divalent cations in a molar ratio of 9: 1 to 1: 9.
- Combinations of 7: 3 to 3: 7 and 6: 4 to 4: 6 are preferred, and the embodiment with the same (1: 1) or almost the same molar amounts of mono- and divalent cations is particularly preferred.
- the total cation concentration in the solution before binding to the solid phase is preferably ⁇ 0.5 M.
- nucleic acids are in a solution that already contains mono- or divalent cations, e.g. B. after a previous lysis of different starting materials, then the existing amount of cations is taken into account when setting the optimal cation concentration according to the invention. If the lysis buffer contains divalent cations that are contained in the solution after lysis, only the required amount of monovalent cations is added (and vice versa).
- washing buffers used according to the invention contain no alcoholic component, as in all other methods of the prior art.
- the use of the buffer formulations according to the invention enables the purification of PCR products from a complex PCR reaction batch for a subsequent sensitive sequencing reaction and without a single washing step in the form of an automated application (binding of the PCR products to the filter membrane of a 96-well plate ) in less than 10 min.
- Previous Methods based on the binding of the nucleic acid to a solid phase require approx. 45 min-1h.
- the procedure is now extremely simple and only includes mixing the PCR mixture with one of the binding buffers according to the invention, transferring the mixture to the feed plate, sucking through the solution and subsequently eluting the PCR products with water or with a 10 mM Tris buffered aqueous solution.
- PCR products can be cleaned extremely quickly, safely and inexpensively.
- the throughput can be increased dramatically (even if equipment costs decrease; e.g. a washing tool is no longer required for a robot).
- the quality of the purified PCR products is very high, which is shown by the clean sequence reactions (example 2).
- nucleic acids can also be isolated from complex biological samples in excellent quality and quantity without washing steps or by means of a washing buffer without alcohol.
- the isolation of a plasmid DNA described in DE 100 33 991 in an example without a washing step was not carried out from the previously prepared, clarified lysate.
- the plasmid DNA to be isolated was first prepared in pure form using known standard methods and this plasmid DNA was incubated again with a buffer, bound to a solid phase and subsequently detached from the solid phase after the necessary removal of the alcohol of the binding buffer.
- the present invention it is now possible to purify plasmid DNA directly from the clarified lysate, again no washing with an alcohol-containing washing buffer is necessary or the plasmid DNA can also be isolated without a washing step directly after binding to a solid phase.
- the plasmid DNA is again of excellent quality and quantity (exemplary embodiment 3).
- the invention also makes it possible to isolate genomic nucleic acids from complex biological samples extremely quickly, inexpensively and simply. For example, only a standard digestion of the starting material is carried out using, for example, a classic protease K digest in a compatible buffer, then the lysed sample is mixed with one of the non-chaotropic binding buffers according to the invention and the mixture is incubated with a nucleic acid-binding solid phase, possibly with a non-alcoholic washing buffer washed (or possibly without a washing step) and subsequently the genomic nucleic acid isolated from the solid phase using water or a Tris solution. The quality of the isolated DNA is again very high and can be used immediately for other applications.
- Another variant of the present invention results from the observation that the pH of the binding buffer used has a significant influence on both the yield of the nucleic acids to be obtained and a selectivity towards the fragment lengths of e.g. PCR products to be purified. It is not necessary to combine mono- and multivalent salts in one solution. Divalent and particularly preferably Mg or Ca salts are preferably used.
- the pH value of the binding buffer exclude small PCR products from isolation.
- surprising effects can be seen from the combination of salt and alcohol in the binding buffer in connection with the choice of pH.
- the alcoholic component in the binding buffer causes a selectivity with regard to the size fractionation of DNA fragments.
- a reduction in the pH of the binding buffer tends to reduce the yield from smaller DNA fragments to complete inhibition of recovery. This is particularly important when heterogeneous sample mixtures are available.
- the pH is adjusted to 5-9.5 and particularly preferably to 8-9.5, 6.5-8 or 5-6.5. This makes it possible to record certain fragment sizes, ie certain fragment sizes are not recovered. It should be pointed out here that the formulation “no recovery” is not to be understood as absolute, ie traces of nucleic acid fragments could always be recovered unspecifically. In the case of binding buffers without alcohol, DNA fragments are recovered in quantitative amounts and over the size range 100 bp bis 10,000 bp preferably at a pH of> 8.5.
- the present invention through the combination of the salt component and alcohol component and the modification of the pH, enables binding buffers to be developed which allow selective recovery of certain nucleic acid fragments to enable heterogeneous initial samples. The present invention thus enables, in universal form, a significant simplification of methods for isolating nucleic acids from complexes containing the nucleic acid samples.
- the process no longer requires toxic chemicals, the amounts of salts used are dramatically reduced, which leads to a significant relief for the environment, the processes require fewer process steps and are therefore significantly faster than all the previously used techniques. In particular in high throughput, inexpensive and extremely fast processes are now available.
- the composition of the buffer formulations can also be used to achieve selective size fractionation of DNA fragments to be recovered.
- Buffer TH 1 (5 mM NaCl; 5 mM MgCl 2 / Tris HCl, isopropanol)
- Buffer TH 2 (10 mM MgCl 2 / Tris HCl, isopropanol)
- Buffer TH 3 (10 mM NaCl / Tris HCl, isopropanol)
- the buffer THl is a combination of a monovalent and a divalent salt with a total ion strength of 10 mM.
- the buffers TH2 and TH3 each contain only one salt (with a monovalent cation or with a divalent cation) at a total strength of 10 mM.
- 130 ⁇ l of the respective buffers were mixed with an aqueous solution of 50 ⁇ l containing a commercial DNA ladder (from FERMENTAS) and the mixture was transferred to a centrifugation column with a glass fiber flow. The mixture was then centrifuged at 10,000 rpm for 1 min and the centrifugation column was transferred to a new reaction vessel.
- the bound fragments are eluted by adding 30 ⁇ l of a 10 mM Tris-HCl solution and subsequent centrifugation for 1 min. The total time for isolating the DNA fragments was therefore only about 2 minutes.
- the eluates obtained were applied to a 1.2% agarose gel and separated electrophoretically. As can be clearly seen in the electrophoretic representation, the DNA fragments can only be recovered efficiently with the combination buffer. In contrast, the binding buffers, each containing only one salt, show only very little binding mediation. (Illustration 1)
- 3 samples were mixed with 800 ⁇ l of a washing buffer without alcohol (10 mM NaCl / 10 mM MgCl 2 / Tris HCl) and centrifuged for 1 min and then the plasmid DNA was eluted from the column with 10 mM Tris-HCl and 3 samples were treated with 70% Washed ethanol, then the ethanol removed and the plasmid DNA again eluted by adding 10 mM Tris HCl.
- a washing buffer without alcohol 10 mM NaCl / 10 mM MgCl 2 / Tris HCl
- the table below illustrates the preparation time required, the quality and quantity of the isolated plasmid DNA.
- Binding buffer each containing 50 mM MgCl 2 and optionally 20% isopropanol as well as 100 mM Tris HCl with varying pH values.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT03767417T ATE454471T1 (de) | 2002-11-08 | 2003-11-10 | Neuartige pufferformulierungen zur isolierung, reinigung und rückgewinnung lang- und kurzkettiger nukleinsäuren |
DE50312324T DE50312324D1 (de) | 2002-11-08 | 2003-11-10 | Nigung und rückgewinnung lang- und kurzkettiger nukleinsäuren |
AU2003291931A AU2003291931A1 (en) | 2002-11-08 | 2003-11-10 | Novel buffer formulations for isolating, purifying and recovering long-chain and short-chain nucleic acids |
EP03767417.3A EP1560926B2 (de) | 2002-11-08 | 2003-11-10 | Neuartige pufferformulierungen zur isolierung, reinigung und rückgewinnung lang- und kurzkettiger nukleinsäuren |
US10/534,387 US20060160085A1 (en) | 2002-11-08 | 2003-11-10 | Novel buffer formulations for isolating purifying and recovering long-chain and short-chain nucleic acids |
US12/408,015 US20090306359A1 (en) | 2002-11-08 | 2009-03-20 | Non-alcoholic buffer formulations for isolating, purifying and recovering long-chain and short-chain nucleic acids |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10252545.5 | 2002-11-08 | ||
DE10252545 | 2002-11-08 | ||
DE10253351A DE10253351B4 (de) | 2002-11-08 | 2002-11-14 | Neuartige Pufferfomulierungen zur Isolierung, Reinigung und Rückgewinnung lang- und kurzkettiger Nukleinsäuren |
DE10253351.2 | 2002-11-14 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/408,015 Continuation-In-Part US20090306359A1 (en) | 2002-11-08 | 2009-03-20 | Non-alcoholic buffer formulations for isolating, purifying and recovering long-chain and short-chain nucleic acids |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004042058A2 true WO2004042058A2 (de) | 2004-05-21 |
WO2004042058A3 WO2004042058A3 (de) | 2004-08-19 |
Family
ID=32313553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2003/003728 WO2004042058A2 (de) | 2002-11-08 | 2003-11-10 | Neuartige pufferformulierungen zur isolierung, reinigung und rückgewinnung lang- und kurzkettiger nukleinsäuren |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060160085A1 (de) |
EP (1) | EP1560926B2 (de) |
AU (1) | AU2003291931A1 (de) |
WO (1) | WO2004042058A2 (de) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007065934A1 (de) * | 2005-12-07 | 2007-06-14 | Aj Innuscreen Gmbh | Verfahren und testkit zur trennung, aufreinigung und wiedergewinnung von lang- und kurzkettigen nukleinsäuren |
WO2007121717A1 (de) | 2006-04-25 | 2007-11-01 | InViTek Gesellschaft für Biotechnik & Biodesign mbH | Formulierungen und verfahren zur isolierung von nukleinsäuren aus beliebigen komplexen ausgangsmaterialien und nachfolgende komplexe genanalytik |
DE102008057317A1 (de) | 2007-11-13 | 2009-09-10 | Stratec Biomedical Systems Ag | Vorrichtung und Verfahren zur Aufreinigung von Biomolekülen |
WO2010026167A1 (de) * | 2008-09-03 | 2010-03-11 | Qiagen Gmbh | Verfahren zum isolieren und reinigen von nukleinsäuren |
EP2264184A1 (de) | 2009-06-22 | 2010-12-22 | Qiagen GmbH | Verfahren zur Amplifikation von DNA unter Verwendung von Tetraethylenglykol, Kit-of-parts dafür und dessen Verwendung |
WO2011083076A1 (en) * | 2010-01-08 | 2011-07-14 | Roche Diagnostics Gmbh | Improved recovery of nucleic acids from magnetic glass particles |
WO2016071535A1 (de) | 2014-11-07 | 2016-05-12 | Aj Innuscreen Gmbh | Verfahren zur selektiven grössenfraktionierten trennung und isolierung von nukleinsäuremischungen |
EP3133159A4 (de) * | 2014-04-18 | 2017-09-06 | Toppan Printing Co., Ltd. | Verfahren zur rückgewinnung von kurzkettigen nukleinsäuren |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070190526A1 (en) * | 2006-02-16 | 2007-08-16 | Nexgen Diagnostics Llc | Methods of extracting nucleic acids |
US8209037B2 (en) * | 2006-10-04 | 2012-06-26 | Ethicon Endo-Surgery, Inc. | Methods and devices for medical treatment |
WO2009111336A2 (en) * | 2008-02-29 | 2009-09-11 | Shizhong Chen | Methods of purifying plasmid dna |
WO2009121208A1 (zh) * | 2008-04-02 | 2009-10-08 | 芮宝生医股份有限公司 | 基于磁性纤维素材料用于分离核酸的试剂、分离促进剂、试剂盒及方法 |
GB0814570D0 (en) * | 2008-08-08 | 2008-09-17 | Diagnostics For The Real World | Isolation of nucleic acid |
DE102008047790A1 (de) * | 2008-09-17 | 2010-04-15 | Qiagen Gmbh | Verfahren zur Normierung des Gehalts von Biomolekülen in einer Probe |
WO2021119043A2 (en) * | 2019-12-09 | 2021-06-17 | Corning Incorporated | Bioactive glass as nucleic acid carriers with ph switch control-releasing |
CN115197935A (zh) * | 2021-04-08 | 2022-10-18 | 上海细胞治疗集团有限公司 | 纤维素色谱纯化rna的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0580305A2 (de) * | 1992-07-02 | 1994-01-26 | Advanced Genetic Technologies Corporation | Verfahren und Material für Reinigung von Nukleinsäuren |
WO2001019980A1 (de) * | 1999-09-10 | 2001-03-22 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Verfahren zum anbinden von nukleinsäuren an eine festphase |
WO2002004620A2 (de) * | 2000-07-12 | 2002-01-17 | Qiagen Gmbh | Verfahren zur isolierung von nukleinsäuren |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1146049B1 (de) † | 1994-02-11 | 2005-08-17 | Qiagen GmbH | Verfahren zur Trennung von Doppelstrang/Einzelstrangnukleinsäurestrukturen |
US5705628A (en) * | 1994-09-20 | 1998-01-06 | Whitehead Institute For Biomedical Research | DNA purification and isolation using magnetic particles |
KR100483498B1 (ko) † | 1996-02-14 | 2005-07-18 | 악조 노벨 엔.브이. | 핵산물질의분리및증폭방법 |
WO1998059076A1 (en) * | 1997-06-25 | 1998-12-30 | Promega Corporation | Method of isolating rna |
US5958677A (en) * | 1997-07-28 | 1999-09-28 | The New York Blood Center, Inc. | Method for purifying viral nucleic acids |
SE9703532D0 (sv) † | 1997-09-30 | 1997-09-30 | Pharmacia Biotech Ab | A process for the purification of plasmid DNA |
DE19856064C2 (de) † | 1998-12-04 | 2000-11-30 | Invitek Gmbh | Universelles Verfahren zur Isolierung von DNA aus beliebigen Ausgangsmaterialien |
US6270970B1 (en) * | 1999-05-14 | 2001-08-07 | Promega Corporation | Mixed-bed solid phase and its use in the isolation of nucleic acids |
DE20207793U1 (de) † | 2002-05-17 | 2002-08-22 | Gl Biotech Gmbh | Kit zur Durchführung eines Verfahrens zur Nukleinsäure-Extraktion und Nukleinsäure-Reinigung |
EP1527172B1 (de) † | 2002-05-17 | 2008-11-26 | Molzym GmbH & Co. KG | Methode für die extraktion und aufreinigung von nukleinsäuren |
-
2003
- 2003-11-10 AU AU2003291931A patent/AU2003291931A1/en not_active Abandoned
- 2003-11-10 WO PCT/DE2003/003728 patent/WO2004042058A2/de not_active Application Discontinuation
- 2003-11-10 US US10/534,387 patent/US20060160085A1/en not_active Abandoned
- 2003-11-10 EP EP03767417.3A patent/EP1560926B2/de not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0580305A2 (de) * | 1992-07-02 | 1994-01-26 | Advanced Genetic Technologies Corporation | Verfahren und Material für Reinigung von Nukleinsäuren |
WO2001019980A1 (de) * | 1999-09-10 | 2001-03-22 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Verfahren zum anbinden von nukleinsäuren an eine festphase |
WO2002004620A2 (de) * | 2000-07-12 | 2002-01-17 | Qiagen Gmbh | Verfahren zur isolierung von nukleinsäuren |
Non-Patent Citations (2)
Title |
---|
LAHIRI D K ET AL: "DNA ISOLATION BY A RAPID METHOD FROM HUMAN BLOOD SAMPLES: EFFECT OF MGCL2, EDTA, STORAGE TIME, AND TEMPERATURE ON DNA YIELD AND QUALITY" BIOCHEMICAL GENETICS, PLENUM PRESS CO., LONDON, GB, Bd. 31, Nr. 7/8, August 1993 (1993-08), Seiten 321-328, XP009007516 ISSN: 0006-2928 * |
See also references of EP1560926A2 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005059217B4 (de) * | 2005-12-07 | 2011-03-17 | Aj Innuscreen Gmbh | Verfahren und Testkit zur Trennung, Aufreinigung und Wiedergewinnung von lang- und kurzkettigen Nukleinsäuren |
US8735068B2 (en) | 2005-12-07 | 2014-05-27 | Aj Innuscreen Gmbh | Method and test kit comprising citric acid salt and alcohol in a binding buffer for the separation, purification and recycling of long- and short-chain nucleic acids |
WO2007065934A1 (de) * | 2005-12-07 | 2007-06-14 | Aj Innuscreen Gmbh | Verfahren und testkit zur trennung, aufreinigung und wiedergewinnung von lang- und kurzkettigen nukleinsäuren |
WO2007121717A1 (de) | 2006-04-25 | 2007-11-01 | InViTek Gesellschaft für Biotechnik & Biodesign mbH | Formulierungen und verfahren zur isolierung von nukleinsäuren aus beliebigen komplexen ausgangsmaterialien und nachfolgende komplexe genanalytik |
EP2010672B1 (de) * | 2006-04-25 | 2011-03-09 | Invitek Gesellschaft Für Biotechnik & Biodesign MBH | Formulierungen und verfahren zur isolierung von nukleinsäuren aus beliebigen komplexen ausgangsmaterialien und nachfolgende komplexe genanalytik |
DE102008057317A1 (de) | 2007-11-13 | 2009-09-10 | Stratec Biomedical Systems Ag | Vorrichtung und Verfahren zur Aufreinigung von Biomolekülen |
US8685322B2 (en) | 2007-11-13 | 2014-04-01 | Stratec Biomedical Ag | Apparatus and method for the purification of biomolecules |
EP2163621A1 (de) * | 2008-09-03 | 2010-03-17 | Qiagen GmbH | Verfahren zum Isolieren und Reinigen von Nukleinsäuren |
US8624020B2 (en) | 2008-09-03 | 2014-01-07 | Qiagen Gmbh | Method for isolating and purifying nucleic acids |
WO2010026167A1 (de) * | 2008-09-03 | 2010-03-11 | Qiagen Gmbh | Verfahren zum isolieren und reinigen von nukleinsäuren |
EP2264184A1 (de) | 2009-06-22 | 2010-12-22 | Qiagen GmbH | Verfahren zur Amplifikation von DNA unter Verwendung von Tetraethylenglykol, Kit-of-parts dafür und dessen Verwendung |
WO2011083076A1 (en) * | 2010-01-08 | 2011-07-14 | Roche Diagnostics Gmbh | Improved recovery of nucleic acids from magnetic glass particles |
CN102834518A (zh) * | 2010-01-08 | 2012-12-19 | 霍夫曼-拉罗奇有限公司 | 改进的从磁性玻璃颗粒中的核酸回收 |
US8420801B2 (en) | 2010-01-08 | 2013-04-16 | Roche Molecular Systems, Inc. | Recovery of nucleic acids from magnetic glass particles |
CN102834518B (zh) * | 2010-01-08 | 2015-04-01 | 霍夫曼-拉罗奇有限公司 | 改进的从磁性玻璃颗粒中的核酸回收 |
EP3133159A4 (de) * | 2014-04-18 | 2017-09-06 | Toppan Printing Co., Ltd. | Verfahren zur rückgewinnung von kurzkettigen nukleinsäuren |
WO2016071535A1 (de) | 2014-11-07 | 2016-05-12 | Aj Innuscreen Gmbh | Verfahren zur selektiven grössenfraktionierten trennung und isolierung von nukleinsäuremischungen |
DE102015222002A1 (de) | 2014-11-07 | 2016-05-12 | Aj Innuscreen Gmbh | Verfahren zur selektiven größenfraktionierten Trennung und Isolierung von Nukleinsäuremischungen |
Also Published As
Publication number | Publication date |
---|---|
AU2003291931A8 (en) | 2004-06-07 |
EP1560926B2 (de) | 2013-08-21 |
WO2004042058A3 (de) | 2004-08-19 |
AU2003291931A1 (en) | 2004-06-07 |
EP1560926B1 (de) | 2010-01-06 |
US20060160085A1 (en) | 2006-07-20 |
EP1560926A2 (de) | 2005-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE19856064C2 (de) | Universelles Verfahren zur Isolierung von DNA aus beliebigen Ausgangsmaterialien | |
EP1146049B1 (de) | Verfahren zur Trennung von Doppelstrang/Einzelstrangnukleinsäurestrukturen | |
EP1960520B1 (de) | Verfahren zur isolierung von nukleinsäuren aus beliebigen ausgangsmaterialien | |
DE4321904B4 (de) | Verfahren zur chromatographischen Reinigung und Trennung von Nucleinsäuregemischen | |
DE69936584T2 (de) | Schnelles und einfaches verfahren zur isolierung von zirkulären nukleinsäuren | |
EP0765335B1 (de) | Universelles verfahren zur isolierung und reinigung von nukleinsäuren aus extrem geringen mengen sowie sehr stark verunreinigten unterschiedlichsten ausgangsmaterialien | |
EP1560926B1 (de) | Neuartige pufferformulierungen zur isolierung, reinigung und rückgewinnung lang- und kurzkettiger nukleinsäuren | |
DE29601618U1 (de) | Vorrichtung zur gleichzeitigen multiplen Isolierung | |
EP1995316A1 (de) | Verfahren zur schonenden Zellaufreinigung, Zellgewinnung und Transfektion von Zellen | |
EP1934347B1 (de) | Verfahren und formulierung zur extraktion von nukleinsäuren aus beliebigen komplexen ausgangsmaterialien | |
EP1960521B1 (de) | Verfahren und testkit zur trennung, aufreinigung und wiedergewinnung von lang- und kurzkettigen nukleinsäuren | |
EP1771242B1 (de) | Verfahren zur effizienten isolierung von nukleinsäuren | |
WO2010026169A2 (de) | Verfahren zum isolieren und reinigen von nukleinsäuren | |
EP2010672B1 (de) | Formulierungen und verfahren zur isolierung von nukleinsäuren aus beliebigen komplexen ausgangsmaterialien und nachfolgende komplexe genanalytik | |
DE10253351B4 (de) | Neuartige Pufferfomulierungen zur Isolierung, Reinigung und Rückgewinnung lang- und kurzkettiger Nukleinsäuren | |
WO2002004620A2 (de) | Verfahren zur isolierung von nukleinsäuren | |
DE19858447A1 (de) | Verfahren zur Isolierung von kurz- und langkettigen Nukleinsäuren | |
DE102007006008B4 (de) | Verfahren und Kit zur Isolierung von Plasmid DNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003767417 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003767417 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006160085 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10534387 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10534387 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |